Zeureka and Sumitomo Pharma Collaborate on Molecule Drug Discovery Research Zeureka and Sumitomo Pharma have signed a research agreement to work on low-molecular drug discovery, aiming to innovate new pharmaceutical candidates together.

Zeureka and Sumitomo Pharma Collaborate on Molecule Drug Discovery Research #Japan #Tokyo #Drug_Discovery #Sumitomo_Pharma #Zeureka

Sumitomo Pharma's DSP-3077 Receives FDA Orphan Drug Designation for RP Treatment Sumitomo Pharma America announces that DSP-3077 has received Orphan Drug designation from the FDA for treating retinitis pigmentosa, addressing urgent patient needs.

Sumitomo Pharma's DSP-3077 Receives FDA Orphan Drug Designation for RP Treatment #United_States #Marlborough #Sumitomo_Pharma #Orphan_Drug #DSP-3077

Sumitomo Pharma Unveils Promising Results for Enzomenib and Nuvisertib in Cancer Treatments New data from Sumitomo Pharma highlights the potential of enzomenib and nuvisertib as innovative treatments for acute leukemia and myelofibrosis, offering hope to patients.

Sumitomo Pharma Unveils Promising Results for Enzomenib and Nuvisertib in Cancer Treatments #USA #Marlborough #Sumitomo_Pharma #Nuvisertib #Enzomenib

Sumitomo Pharma America Receives Orphan Drug Designation in Europe for Nuvisertib to Treat Myelofibrosis Sumitomo Pharma America is thrilled to receive Orphan Drug Designation from the European Medicines Agency for nuvisertib to treat myelofibrosis, following its FDA Fast Track designation.

Sumitomo Pharma America Receives Orphan Drug Designation in Europe for Nuvisertib to Treat Myelofibrosis #United_States #Marlborough #Sumitomo_Pharma #Myelofibrosis #Nuvisertib

Sumitomo Pharma America Gains FDA Fast Track Designation for Nuvisertib in Myelofibrosis Treatment Sumitomo Pharma America has announced that Nuvisertib has been granted FDA Fast Track Designation to treat myelofibrosis, showcasing promise in clinical trials.

Sumitomo Pharma America Gains FDA Fast Track Designation for Nuvisertib in Myelofibrosis Treatment #USA #Marlborough #Sumitomo_Pharma #Myelofibrosis #Nuvisertib

Sumitomo Pharma America Shares Promising Vibegron Data at AUA 2025 Annual Meeting Sumitomo Pharma America revealed new findings about Vibegron, emphasizing its safety and effectiveness for men with OAB and BPH at AUA 2025.

Sumitomo Pharma America Shares Promising Vibegron Data at AUA 2025 Annual Meeting #United_States #Marlborough #Sumitomo_Pharma #Vibegron #BPH

Sumitomo Pharma America Partners with National Cancer Institute to Explore Enzomenib for Cancer Therapy In a groundbreaking collaboration, Sumitomo Pharma America has signed a CRADA with the NCI to advance the clinical evaluation of enzomenib, an innovative cancer therapy.

Sumitomo Pharma America Partners with National Cancer Institute to Explore Enzomenib for Cancer Therapy #USA #Marlborough #Sumitomo_Pharma #Enzomenib #NCI

Sumitomo Pharma America Gains FDA Approval for GEMTESA® to Treat OAB Symptoms in Men with BPH Sumitomo Pharma America announces FDA approval of GEMTESA® (vibegron) for men with overactive bladder symptoms linked to benign prostatic hyperplasia, enhancing treatment options.

Sumitomo Pharma America Gains FDA Approval for GEMTESA® to Treat OAB Symptoms in Men with BPH #USA #Marlborough #GEMTESA #Sumitomo_Pharma #Overactive_Bladder

Exciting Clinical Advances in Blood Cancer Treatments at ASH 2024: Nuvisertib and Enzomenib Sumitomo Pharma America's latest research at the ASH 2024 Annual Meeting showcases promising data for Nuvisertib and Enzomenib in treating relapsed/refractory cancers.

Exciting Clinical Advances in Blood Cancer Treatments at ASH 2024: Nuvisertib and Enzomenib #United_States #Marlborough #Sumitomo_Pharma #Nuvisertib #Enzomenib

Encouraging Patients with Overactive Bladder to Seek Treatment Through Time To Go Campaign Sumitomo Pharma America's partnership with Holly Robinson Peete aims to raise awareness about overactive bladder and encourage patients to seek treatment.

Encouraging Patients with Overactive Bladder to Seek Treatment Through Time To Go Campaign #USA #Marlborough #Holly_Robinson_Peete #GEMTESA #Sumitomo_Pharma